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Report on the
Jefferson Industry Advisory Council Meeting
___________________________________________________________________
Defining and negotiating the relations between academic providers of medical
education programs and pharmaceutical industry sponsors formed the focus of the
second meeting of the Jefferson Industry Advisory Council (JIAC) on July 17, 2003.
Thirty persons attended, fourteen representing pharmaceutical companies and
sixteen Jefferson physicians, department heads and administrators.
Recent concerns about the encroachments of commerce into medical professionalism
have made the questions raised at the JIAC meeting urgent. On September 10,
2002, the Accreditation Council for Graduate Medical Education (ACGME) released a
draft of new standards relating to the sponsorship of continuing medical education
(CME) activities by drug companies. The draft states that “the conflict of values
between the professional ethics of the physician and the business ethics of industry
is impossible to ignore.”1, An even stronger position was taken by Dr. Arnold Relman
of Harvard Medical School, who charged in a May 14, 2003, commentary in the
Journal of the American Medical Association that “the growing intrusion of the
pharmaceutical companies into medical education” is an issue of the first importance
to the medical profession and that there should be “no equivocation” about the
necessity for separating professional CME from the marketing and promotional
campaigns of drug companies.2
Recent events have only underscored these words. A June 29, 2003, article in The
Boston Globe (“Hospital, drug firm relations probed”) described how federal
investigators are probing pharmaceutical marketing practices, doctor-drug sales
representative interactions, and possible anti-kickback violations.3 Subpoenas have
been served to many top academic medical centers in Boston and elsewhere,
although so far only Tufts-New England Medical Center has confirmed that it was
investigated last fall in connection with an AstraZeneca sales promotion.
More sensationally, in July of this year, Dateline NBC featured an interview with
David Franklin, former Warner-Lambert sales representative and medical science
liaison officer, who blew the whistle on illegal encouragement of off-label use of
medications.4 Franklin testified that he had been involved in deceptive sales
practices, one of which involved introducing himself as Dr. Franklin and allowing the
physician to assume he was a medical doctor rather than a PhD.
Given these developments, the JIAC felt it was important to begin formulating
standards that would apply to the medical/academic community at Jefferson in its
interactions with pharmaceutical companies. After an opening welcome by Geno J.
Merli, MD, the Ludwig Kind Professor of Medicine and Senior Associate Dean of
Continuing Medical Education, Dr. David Nash, Director of the Office of Health Policy
and Clinical Outcomes, spoke on the “Environmental Scan: Industry and Medical
Education.” Dr. Nash stressed that academia and industry need each other; from
that mutual need a morally appropriate interaction can be developed, for it is
important to maintain the benefits of continuing medical education programs.
Sponsorship by industry for some of these programs is essential.
Dr. Nash thought that excessive sales initiatives by industry and pharmaceutical
companies in medical education could be considered the medical equivalent of
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corporate malfeasance of the likes of Enron and others. The recent exposures of such
practices has meant that “the days of drug company sales reps in hospital rooms”
are over. Yet, the consensus in the meeting was that a middle ground could be found
– not by completely banning the presence of pharmaceutical companies in situ, but
by making clear distinctions between educational and marketing activities. While
medical schools must retain all responsibility for the conduct and content of CME
courses, they might be positioned to offer tailored, academic, evidence-based
instruction not only to physicians but to industry representatives as well. Implicit in
the relationship between academic medical centers and industry is the establishment
of safeguards to ensure compliance with HIPAA regulations in addition to university
and hospital policies and procedures. It is important that all parties know who is onsite and why they are there. A central registry for all non-patient related visitors is
one possibility.
Other highlights of the meeting included a presentation by Jeff Fetterman, President,
ParagonRx, on “Applying Principles of Adult Education to CME,” and presentations by
Jefferson faculty members Howard Greenberg, MD, Medical Director of the Clinical
Research Unit; Edward Tawyea, PhD, Director of Academic Information Services and
Research; Neil Goldfarb, Director of Research, Office of Health Policy and Clinical
Outcomes; and Richard Wender, MD, Alumni Professor and Chair, Department of
Family Medicine. All presentations provided current examples of creative and
innovative approaches to learning in the academic/industry partnership.
JIAC members agreed that innovation is the key to adaptation. Not only is the future
of CME at stake, but pharmaceutical company leaders must realize that their
continued business depends in a fundamental way upon public confidence in doctors
and the medical practice. The separation of marketing from educational functions will
necessitate new ways of evaluating pharmaceutical company return on investment.
As one committee member put it, “We can’t even use the term “return on
investment” anymore.” The current term, he said, is “commitment instrument.” A
return on investment points to a purely financial interest, whereas a commitment
instrument implies a commitment to the educational and research basis of all
developed products.
Participants of the Jefferson Industry Advisory Council meeting recognized the
challenges facing the academic/industry partnership, but there was also the sense
that these challenges could be turned into opportunities. Both sides of the
partnership showed the ability to face facts combined with willingness to discuss
guidelines for new and creative ways of working together. It was an important step
in defining what the respective roles of academia and industry are to be, and more
discussions are expected to follow when JIAC meets again in 2004. Please address
questions and comments to Jeanne Cole, MS, Director, Jefferson Medical College
Office of Continuing Medical Education, at jeanne.cole@jefferson.edu.
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